---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269722"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:00:47.703676+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports Q3 2025 results, announces $1.085B Chugai collaboration and $60.3M financing

## Summary
- Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.
- Closed $60.3M oversubscribed private placement led by Samsara BioCapital with participation from RA Capital, Anomaly, Special Situations Funds, and Invus.
- Appointed Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board of Directors.
- Cash runway expected into 2028; Phase 1 trial of oral obesity therapy RT-114 planned by end of 2025.
- Net loss for Q3 2025 was $7.9M, improved from $12.7M in prior year period.

## SEC filing metadata
- accession: 0001193125-25-269722
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/0001193125-25-269722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312525269722/rani-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269722
- JSON: https://secwatch.observer/filing/0001193125-25-269722.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.